| Matthew Willis Parsons, MD | |
|
22 Bramhall St, Portland, ME 04102-3134 | |
| (072) 662-2276 | |
| Not Available |
| Full Name | Matthew Willis Parsons |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 7 Years |
| Location | 22 Bramhall St, Portland, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427581560 | NPI | - | NPPES |
| 1427581560 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 10957219-1205 (Utah) | Secondary |
| 2085R0001X | Radiology - Radiation Oncology | MD25306 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Southern Maine Health Care | Biddeford, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Spectrum Healthcare Partners Pa | 7618871245 | 265 |
News Archive
A subset of children with asthma suffers from severe, treatment-resistant disease associated with more illness and greater allergic hypersensitivity, according to the results of the National Heart, Blood, and Lung Institute's Severe Asthma Research Program, presented in a recently published article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc..
Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc. today announced that the Marketing Authorization Application (MAA) for OraVerse has been accepted for review by the regulatory agencies of the United Kingdom (UK), Germany, Italy, France and Spain. OraVerse is the first and only local anesthesia reversal agent that accelerates the return of normal sensation and function following routine dental procedures. OraVerse is approved for use in the U.S. by the Food and Drug Administration and sold by Novalar direct to U.S. dentists.
Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.
LTC Properties, Inc. announced today that it had declared a monthly cash dividend on its common stock for the first quarter of 2011.
Shire plc, the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE).
› Verified 4 days ago
| Entity Name | Spectrum Healthcare Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669488011 PECOS PAC ID: 7618871245 Enrollment ID: O20040423000266 |
News Archive
A subset of children with asthma suffers from severe, treatment-resistant disease associated with more illness and greater allergic hypersensitivity, according to the results of the National Heart, Blood, and Lung Institute's Severe Asthma Research Program, presented in a recently published article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc..
Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc. today announced that the Marketing Authorization Application (MAA) for OraVerse has been accepted for review by the regulatory agencies of the United Kingdom (UK), Germany, Italy, France and Spain. OraVerse is the first and only local anesthesia reversal agent that accelerates the return of normal sensation and function following routine dental procedures. OraVerse is approved for use in the U.S. by the Food and Drug Administration and sold by Novalar direct to U.S. dentists.
Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.
LTC Properties, Inc. announced today that it had declared a monthly cash dividend on its common stock for the first quarter of 2011.
Shire plc, the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE).
› Verified 4 days ago
| Entity Name | Spectrum Healthcare Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669488011 PECOS PAC ID: 7618871245 Enrollment ID: O20040423000305 |
News Archive
A subset of children with asthma suffers from severe, treatment-resistant disease associated with more illness and greater allergic hypersensitivity, according to the results of the National Heart, Blood, and Lung Institute's Severe Asthma Research Program, presented in a recently published article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc..
Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc. today announced that the Marketing Authorization Application (MAA) for OraVerse has been accepted for review by the regulatory agencies of the United Kingdom (UK), Germany, Italy, France and Spain. OraVerse is the first and only local anesthesia reversal agent that accelerates the return of normal sensation and function following routine dental procedures. OraVerse is approved for use in the U.S. by the Food and Drug Administration and sold by Novalar direct to U.S. dentists.
Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.
LTC Properties, Inc. announced today that it had declared a monthly cash dividend on its common stock for the first quarter of 2011.
Shire plc, the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Willis Parsons, MD 324 Gannett Dr Ste 200, South Portland, ME 04106-3266 Ph: (207) 482-7800 | Matthew Willis Parsons, MD 22 Bramhall St, Portland, ME 04102-3134 Ph: (072) 662-2276 |
News Archive
A subset of children with asthma suffers from severe, treatment-resistant disease associated with more illness and greater allergic hypersensitivity, according to the results of the National Heart, Blood, and Lung Institute's Severe Asthma Research Program, presented in a recently published article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc..
Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc. today announced that the Marketing Authorization Application (MAA) for OraVerse has been accepted for review by the regulatory agencies of the United Kingdom (UK), Germany, Italy, France and Spain. OraVerse is the first and only local anesthesia reversal agent that accelerates the return of normal sensation and function following routine dental procedures. OraVerse is approved for use in the U.S. by the Food and Drug Administration and sold by Novalar direct to U.S. dentists.
Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.
LTC Properties, Inc. announced today that it had declared a monthly cash dividend on its common stock for the first quarter of 2011.
Shire plc, the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE).
› Verified 4 days ago
Michael O'malley Quinn, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2571 | |
Elena Leah Resnick, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2571 | |
Matthew D Ralston, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2571 | |
Jerald Christopher Kuhn, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 144 State St, Portland, ME 04101 Phone: 207-879-3000 | |
Whitney Beeler, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-4735 Fax: 207-662-6388 | |
David Russell Langdon, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 144 State St, Portland, ME 04101 Phone: 207-879-3000 | |
Ethan M Dobrow, MD Radiology Medicare: Medicare Enrolled Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2526 |